Evidence map›Paper›PMID 33709236›Full record

ReviewAAPS PharmSciTech2021

Container Closure and Delivery Considerations for Intravitreal Drug Administration.

Ashwin C Parenky, Saurabh Wadhwa, Hunter H Chen, Amardeep S Bhalla, Kenneth S Graham, Mohammed Shameem

Open access · hybridAbstract readReview
In one paragraph

Review in AAPS PharmSciTech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Intravitreal injection delivered volume under different environmental and training conditions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ashwin C ParenkyFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA.
Saurabh WadhwaFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA.
Hunter H ChenFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA. hunter.chen@regeneron.com.
Amardeep S BhallaFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA.
Kenneth S GrahamFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA.
Mohammed ShameemFormulations Development, Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road Tarrytown, New York, 10591, USA.
Regeneron (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravitreal (IVT) administration of therapeutics is the standard of care for treatment of back-of-eye disorders. Although a common procedure performed by retinal specialists, IVT administration is associated with unique challenges related to drug product, device and the procedure, which may result in adverse events. Container closure configuration plays a crucial role in maintaining product stability, safety, and efficacy for the intended shelf-life. Careful design of primary container configuration is also important to accurately deliver small volumes (10-100 μL). Over- or under-dosing may lead to undesired adverse events or lack of efficacy resulting in unpredictable and variable clinical responses. IVT drug products have been traditionally presented in glass vials. However, pre-filled syringes offer a more convenient administration option by reducing the number of steps required for dose preparation there by potentially reducing the time demand on the healthcare providers. In addition to primary container selection, product development studies should focus on, among other things, primary container component characterization, material compatibility with the formulation, formulation stability, fill volume determination, extractables/leachables, and terminal sterilization. Ancillary components such as disposable syringes and needles must be carefully selected, and a detailed administration procedure that includes dosing instructions is required to ensure successful administration of the product. Despite significant efforts in improving the drug product and administration procedures, ocular safety concerns such as endophthalmitis, increased intraocular pressure, and presence of silicone floaters have been reported. A systematic review of available literature on container closure and devices for IVT administration can help guide successful product development.

Indexed as

SyringesDrug Delivery SystemsDrug PackagingHumansIntravitreal InjectionsNeedlesPharmaceutical PreparationsSterilizationPharmaceutical PreparationsFormulationNeedleOcularSterilizationSyringe

Identifiers

PMID33709236
PMCPMC7952281
OpenAlexW3135162543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.